Gland Pharma (GLAND.NS) Financial Analysis & Valuation | Quarter Chart
Gland Pharma (GLAND.NS)
GLAND.NSPrice: $17.93
Fair Value: 🔒
🔒score
Gland Pharma Limited engages in the development, manufacture, and marketing of injectable-focused generic liquid parenteral products. The company's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its produc... more
Gland Pharma Limited engages in the development, manufacture, and marketing of injectable-focused ge... more
Description
Shares
| Market Cap | $2.95B | Exchange | NSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | IN | CEO | Shyamakant Giri |
| IPO Date | 2020-11-20 | CAGR | 0.18% |
| Employees | 4,217 | Website | www.glandpharma.com |
| Div. Yield | 40343.68% | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | 40343.68% |
GLAND.NS chart loading...
Fundamentals
Technicals
| Enterprise Value | $301.43B | P/E Ratio | 32.56 |
| Forward P/E | 24.35 | PEG Ratio | 1.23 |
| P/S Ratio | 0.02 | P/B Ratio | 0.02 |
| P/CF Ratio | — | P/FCF Ratio | — |
| EPS | $0.55 | EPS Growth 1Y | 6.64% |
| EPS Growth 3Y | -29.46% | EPS Growth 5Y | -14.41% |
| Revenue Growth 1Y | -2.34% | Gross Margin | 0.55% |
| Operating Margin | 0.21% | Profit Margin | 0.13% |
| ROE | 0.09% | ROA | — |
| ROCE | — | Current Ratio | — |
| Quick Ratio | — | Cash Ratio | — |
| Debt/Equity | — | Interest Coverage | 24.94 |
| Altman Z Score | — | Piotroski Score | 4 |